Group 1 - Aofei Data achieved a net profit of 87.89 million yuan in the first half of 2025, a year-on-year increase of 16.09% [1] - Aofei Data's revenue for the same period was 1.148 billion yuan, up 8.20% year-on-year [1] - The company specializes in IDC services, internet business, system integration, and distributed photovoltaic energy-saving services [1] Group 2 - Meilan De reported a net profit of 63.92 million yuan, a year-on-year decrease of 11.96% [1] - The company's revenue was 241 million yuan, reflecting a growth of 5.62% year-on-year [1] - Meilan De focuses on the research, production, sales, and service of medical devices related to pelvic and obstetric rehabilitation [1] Group 3 - Jiuan Medical posted a net profit of 920 million yuan, a significant year-on-year increase of 52.91% [1] - The company's revenue decreased by 43.35% to 765 million yuan [1] - Jiuan Medical specializes in the research, production, and sales of home medical devices [2] Group 4 - Hanbang Technology's net profit fell by 26.24% to 27.80 million yuan [2] - The company achieved a revenue of 349 million yuan, a growth of 5.99% year-on-year [2] - Hanbang Technology provides professional separation and purification equipment, consumables, and technical solutions for the pharmaceutical and life sciences sectors [2] Group 5 - Jinjing Environment reported a net profit of 78.69 million yuan, a year-on-year increase of 13.73% [2] - The company's revenue was 782 million yuan, reflecting a growth of 1.70% [2] - Jinjing Environment focuses on investment operation management services and equipment manufacturing in the environmental sanitation sector [2] Group 6 - Tianbao Infrastructure achieved a net profit of 118 million yuan, a remarkable year-on-year increase of 2106.58% [3] - The company's revenue decreased by 8.31% to 486 million yuan [3] - Tianbao Infrastructure is involved in real estate development, property leasing, and management [4] Group 7 - Weihuaxin Materials reported a net profit of 83.15 million yuan, a year-on-year decrease of 52.91% [5] - The company's revenue was 437 million yuan, down 30.71% year-on-year [5] - Weihuaxin Materials specializes in the research and production of chlorotoluene and trifluoromethylbenzene products [5] Group 8 - Tianchen Medical posted a net profit of 48.21 million yuan, a year-on-year increase of 67.10% [6] - The company's revenue was 156 million yuan, reflecting a growth of 17.66% [6] - Tianchen Medical focuses on the research, innovation, and production of high-end surgical staplers [6] Group 9 - Greenland Holdings reported a net loss of 3.506 billion yuan in the first half of 2025 [8] - The company's revenue was 9.45 billion yuan, down 18.06% year-on-year [8] - Greenland Holdings is involved in various financial services including securities, futures, and trust [8] Group 10 - Wukuang Capital's net profit decreased by 41.47% to 525 million yuan [9] - The company achieved a total revenue of 623 million yuan, a significant increase of 144.86% [9] - Wukuang Capital operates in the financial sector, providing services such as securities and leasing [9] Group 11 - Yutong Technology reported a net profit of 554 million yuan, a year-on-year increase of 11.42% [10] - The company's revenue was 7.876 billion yuan, reflecting a growth of 7.10% [10] - Yutong Technology specializes in the research, design, production, and sales of paper packaging products [10] Group 12 - Wewei Co. posted a net profit of 120 million yuan, a year-on-year decrease of 20.14% [11] - The company's revenue was 1.521 billion yuan, down 12.76% year-on-year [11] - Wewei Co. focuses on the production and sales of various food and beverage products [11] Group 13 - Tongfang Co. reported a net loss of 256 million yuan in the first half of 2025 [12] - The company's revenue was 5.667 billion yuan, down 10.09% year-on-year [12] - Tongfang Co. is engaged in the development of smart technology and nuclear technology applications [12] Group 14 - Liugang Co. achieved a net profit of 368 million yuan, a year-on-year increase of 579.54% [13] - The company's revenue was 34.675 billion yuan, down 8.32% [13] - Liugang Co. specializes in coke, sintering, iron, steel smelting, and steel processing [13] Group 15 - China National Petroleum Corporation reported a net profit of 83.993 billion yuan, with a proposed dividend of 0.22 yuan per share [14] - The company's revenue was 1.45 trillion yuan, down 6.7% year-on-year [14] - The company is involved in oil and gas exploration, production, refining, and sales [14] Group 16 - Fangda Carbon's net profit decreased by 68.31% to 54.53 million yuan [15] - The company's revenue was 1.690 billion yuan, down 28.13% year-on-year [15] - Fangda Carbon specializes in the research, production, and sales of graphite and carbon materials [15] Group 17 - Xinmai Medical reported a net profit of 31.5 million yuan, a year-on-year decrease of 22.03% [18] - The company's revenue was 714 million yuan, down 9.24% year-on-year [18] - Xinmai Medical focuses on the research, production, and sales of vascular intervention medical devices [18] Group 18 - Hengbao Co. posted a net profit of 35.35 million yuan, a year-on-year decrease of 44.41% [19] - The company's revenue was 430 million yuan, down 8.64% year-on-year [19] - Hengbao Co. specializes in high-end intelligent products and digital security solutions [19] Group 19 - Zhongji Xuchuang reported a net profit of 3.995 billion yuan, a year-on-year increase of 69.40% [20] - The company's revenue was 14.789 billion yuan, reflecting a growth of 36.95% [20] - Zhongji Xuchuang specializes in high-end optical communication modules and devices [20] Group 20 - Guangxian Media achieved a net profit of 2.229 billion yuan, a year-on-year increase of 371.55% [21] - The company's revenue was 3.242 billion yuan, up 143.00% year-on-year [21] - Guangxian Media focuses on investment, production, and distribution of film projects [21] Group 21 - Huarun Pharmaceutical reported a net profit of 37.33 million yuan, a year-on-year decrease of 49.01% [23] - The company's revenue was 624 million yuan, down 19.13% year-on-year [23] - Huarun Pharmaceutical specializes in pharmaceuticals, medical devices, and health products [23] Group 22 - Huawai Technology posted a net profit of 12.7 million yuan, a year-on-year increase of 56.18% [24] - The company's revenue was 937 million yuan, reflecting a growth of 32.62% [24] - Huawai Technology focuses on the research, production, and sales of high-end elastic components [24]

证券代码：603310 证券简称：巍华新材 公告编号：2025-044 本次会议的召集、召开符合《中华人民共和国公司法》《浙江巍华新材料股 份有限公司章程》（以下简称《公司章程》）的有关规定，会议决议合法、有效。 浙江巍华新材料股份有限公司 第四届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江巍华新材料股份有限公司（以下简称"公司"）第四届董事会第二十五 次会议通知于 2025 年 8 月 15 日通过电话或电子邮件方式向全体董事发出，会议 于 2025 年 8 月 26 日在公司 301 会议室以现场投票及通讯表决相结合方式召开。 本次会议由董事长吴江伟先生召集主持，应出席董事 7 人，实际出席董事 7 人。 公司高级管理人员列席会议。 二、董事会会议审议情况 与会董事对本次会议的全部议案进行了认真审议，以记名投票方式表决并作 出如下决议： （一）审议通过《关于<2025 年半年度报告>及摘要的议案》 表决结果：7 票同意，0 票反对，0 票弃权，0 票回避。 本议 ...

Core Viewpoint - Wihua New Materials (603310) reported a significant decline in both revenue and net profit for the first half of 2025, indicating challenges in the agricultural chemical sector and increased market competition [1] Financial Performance - The company achieved an operating income of 437 million yuan, a year-on-year decrease of 30.71% [1] - The net profit attributable to shareholders was 83.15 million yuan, down 52.91% year-on-year [1] - Basic earnings per share were reported at 0.24 yuan [1] Industry Challenges - The decline in sales volume and prices of the company's main products was influenced by reduced demand from the downstream agricultural chemical industry [1] - Increased supply from competitors in the niche market has intensified competition, significantly squeezing the company's revenue potential [1] - The subsidiary Fanghua's project on trifluoromethyl pyridine is still in the trial production phase, leading to high startup costs [1]

中信建投证券股份有限公司 关于浙江巍华新材料股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为浙江巍华新材料股份有限公司（以下简称"巍华新材"或"公司"）首次公 开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交 易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等有关规定，对巍华新材使用部分暂时闲置募集资金进行现金管理事项进行 了审慎核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意浙江巍华新材料股份有限公司首次 公开发行股票注册的批复》（证监许可[2023]2608 号），并经上海证券交易所同意， 公司首次公开发行人民币普通股（A 股）8,634.00 万股，每股面值为人民币 1.00 元，每股发行价 17.39 元，募集资金总额为 150,145.26 万元，扣除本次股票发行 累计发生的发行费用（不含增值税）8,988.45 万元，实际募集资金净额为 141,156.81 万元。立信会计师事务所（特殊普通合伙）已于 2024 年 8 月 9 ...

Core Viewpoint - Wihua New Materials (603310.SH) reported a significant decline in both revenue and net profit for the first half of 2025 compared to the previous year [1] Financial Performance - The company achieved total operating revenue of 437 million yuan, representing a year-on-year decrease of 30.71% [1] - The net profit attributable to shareholders was 83.15 million yuan, down 52.91% year-on-year [1] - Basic earnings per share were reported at 0.24 yuan [1]

Core Viewpoint - Zhejiang Weihua New Material Co., Ltd. reported a significant decline in revenue and profit for the first half of 2025, primarily due to decreased demand in the agricultural chemical sector and increased competition in the fluorochemical industry [2][10][12]. Company Overview and Financial Indicators - The company generated revenue of approximately 437.26 million yuan, a decrease of 30.71% compared to the same period last year [3]. - Total profit amounted to about 90.66 million yuan, down 55.56% year-on-year [3]. - Net profit attributable to shareholders was approximately 83.15 million yuan, reflecting a 52.91% decline compared to the previous year [3]. - The company's net assets were reported at approximately 3.94 billion yuan, a slight decrease of 0.50% from the end of the previous year [3]. Industry and Business Analysis - The fluorochemical industry is a rapidly growing sector within the chemical industry, with a market size projected to reach 50 billion yuan by 2024 [5]. - The production of fluorinated fine chemicals is a key focus, with the industry expected to see a compound annual growth rate of 5.58% from 2023 to 2027 [5]. - The company specializes in the production of chlorobenzene and trifluoromethylbenzene series products, which are essential for various applications in agriculture, pharmaceuticals, and fine chemicals [7][9]. Market Position and Competitive Advantage - The company is recognized as a leading player in the trifluoromethylbenzene market, benefiting from a complete industrial chain and advanced production technologies [10][19]. - The company has established strong partnerships with major clients, including BAYER and BASF, enhancing its market reputation and customer loyalty [19]. - Continuous investment in research and development has led to significant technological advancements, allowing the company to maintain a competitive edge in production efficiency and product quality [16][18]. Operational Challenges and Strategic Initiatives - The company faced challenges due to a decline in market demand and increased competition, leading to a drop in sales prices and volumes [10][12]. - To address these challenges, the company is focusing on expanding its production capacity and enhancing its product offerings through innovation and strategic partnerships [14][19]. - The company is also committed to improving operational efficiency and safety through continuous process optimization and employee engagement initiatives [14][16].

| 浙江巍华新材料股份有限公司2025 | 年半年度报告摘要 | | | | | --- | --- | --- | --- | --- | | 公司代码：603310 | 公司简称：巍华新材 | | | | | 浙江巍华新材料股份有限公司 | | | | | | 浙江巍华新材料股份有限公司2025 | 年半年度报告摘要 | | | | | | 第一节 重要提示 | | | | | 展规划，投资者应当到 | http://www.sse.com.cn/网站仔细阅读半年度报告全文。 | | | | | 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | | | | 不适用 | | | | | | 第二节 | 公司基本情况 | | | | | | 公司股票简况 | | | | | 股票种类 股票上市交易所 | 股票简称 | 股票代码 | | 变更前股票 | | 简称 | | | | | | A股 上海证券交易所 | 巍华新材 603310 | | 不适用 | | | 联系人和联系方式 | 董事会秘书 | | 证券事务代表 | | | 姓名 任安立 | 沈勇虎 | | | | | 电话 | ...

Meeting Overview - The fourth meeting of the board of directors of Zhejiang Wehua New Materials Co., Ltd. was held on August 26, 2025, with all 7 directors present, ensuring compliance with relevant laws and regulations [1][2]. Resolutions Passed - The board approved the "2025 Half-Year Report" and its summary with a unanimous vote of 7 in favor [1][2]. - The board also approved the "Special Report on the Storage and Actual Use of Raised Funds for the First Half of 2025," again with a unanimous vote of 7 in favor [2]. - The board authorized the use of up to 700 million yuan of temporarily idle raised funds for cash management, allowing investments in safe and liquid financial products with a maximum term of 12 months [2][3].

证券代码：603310 证券简称：巍华新材 公告编号：2025-046 浙江巍华新材料股份有限公司 本公司及董事会全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 现金管理受托方：银行等具有合法经营资格的金融机构。 ? 现金管理产品：安全性高、流动性好的结构性存款、大额存单等保本 型产品，产品期限不超过 12 个月，该等现金管理产品不得用于质押。现金管理 仅限于在募集资金专项账户或者公开披露的产品专用结算账户实施。 ? 现金管理额度及期限：不超过人民币 70,000 万元（单日最高余额，含 本数），该额度自董事会审议通过该议案之日起 12 个月内可循环滚动使用。 ? 已履行审议程序：浙江巍华新材料股份有限公司（以下简称"公司"） 召开第四届董事会第二十五次会议，审议通过《关于使用部分暂时闲置募集资金 进行现金管理的议案》，本议案不涉及关联交易。保荐机构中信建投证券股份有 限公司出具了无异议的核查意见。本事项无须提交公司股东会审议。 合计 166,828.10 141,156.81 70,081.10 公司正在有序推进募集资 ...

Core Points - Zhejiang Wehua New Materials Co., Ltd. successfully raised a total of RMB 141,156.81 million through its initial public offering, with the funds fully received and verified by an accounting firm [1][2][3] - The company has established a dedicated account for the raised funds, ensuring that the funds are used strictly for their intended purposes, in compliance with relevant regulations [2][4] - As of June 30, 2025, the company has utilized RMB 70,081.10 million of the raised funds, with a remaining balance of RMB 28,791.23 million in the dedicated account [3][4][5] Fund Management - The company has signed tripartite supervision agreements with its underwriters and banks to ensure proper management of the raised funds [2][4] - The funds are stored in dedicated accounts at China Construction Bank, China Merchants Bank, and CITIC Bank [3][4] - The company has implemented a cash management plan for temporarily idle funds, allowing for investment in low-risk financial products, with a maximum of RMB 120,000.00 million allocated for such investments [4][5] Fund Usage - The actual use of raised funds for investment projects during the reporting period amounted to RMB 10,140.78 million [3][6] - The company has replaced RMB 47,916.27 million of self-raised funds used for investment projects with the raised funds, which has been approved by the board and verified by an accounting firm [3][6] - There were no instances of using idle funds for temporary working capital or any other unauthorized purposes during the reporting period [4][6] Project Status - The company has not made any changes to the planned investment projects during the reporting period [4][6] - All investment projects are currently in the construction phase, and there have been no significant changes in project feasibility [6]